| Drug Type Bispecific antibody | 
| Synonyms anti-SPARC scFv + anti-RANKL IgG | 
| Target | 
| Action inhibitors | 
| Mechanism RANK inhibitors(TNF receptor superfamily member 11a inhibitors), SPARC inhibitors(secreted protein acidic and cysteine rich inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedDiscovery | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Osteoporosis | Discovery | Taiwan Province  | - | 






